Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:47:59.866Z.
Calculation as of: 2026-10-06T16:47:59.866Z.
Quote observation: 2026-10-06T16:45:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19f1946388931e4ee5326c5171249fc23a65b0c9e42408d49e268755c1a57655
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$945.04M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$953.38M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$916.63M
EV/EBIT Ratio
34.26x
TTM Avg
30.80x
3Y Avg
40.41x
5Y Avg
53.37x
Market Cap
$984.09M
EV/EBIT Ratio
64.53x
TTM Avg
51.40x
3Y Avg
38.19x
5Y Avg
39.85x
Market Cap
$985.37M
EV/EBIT Ratio
5.19x
TTM Avg
6.47x
3Y Avg
6.47x
5Y Avg
6.47x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | $950.24M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $945.04M | N/A | N/A | N/A | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $953.38M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $928.45M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $931.87M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $980.51M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $916.63M | 34.26x | 30.80x | 40.41x | 53.37x |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.09M | 64.53x | 51.40x | 38.19x | 39.85x |
| MeiraGTx Holdings plc (MGTX)vs › | $985.37M | 5.19x | 6.47x | 6.47x | 6.47x |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $990.37M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
